EDIT
Editas Medicine, Inc.
There isn't enough reported data to score EDIT yet.
EDIT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
EDIT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
EDIT PE Valuation
EDIT has no meaningful PE right now: it lost money over the past year.
EDIT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect EDIT's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
EDIT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.62 | +$1.76 |
| Q2 2026 | -$0.75 | +$2.10 |
| Q1 2026 | -$1.23 | +$1.81 |
| Q4 2025 | -$1.89 | +$0.99 |
| Q3 2025 | -$2.38 | +$0.15 |
| Q2 2025 | -$2.85 | -$0.52 |
| Q1 2025 | -$3.04 | -$0.97 |
| Q4 2024 | -$2.88 | -$0.86 |
EDIT is still losing money, but far less than before: $0.62 per share over the past year, against $3.24 at its worst in late 2021.
EDIT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.4M | +37% |
| Q2 2026 | $11.9M | +232% |
| Q1 2026 | $2.8M | -39% |
| Q4 2025 | $24.7M | -19% |
| Q3 2025 | $7.5M | +12266% |
| Q2 2025 | $3.6M | +597% |
| Q1 2025 | $4.7M | +310% |
| Q4 2024 | $30.6M | -49% |
EDIT's revenue is recovering but still below its 2020 peak: $10M last quarter, up 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -234% | +91 points |
| Q2 2026 | -156% | +1285 points |
| Q1 2026 | -883% | +752 points |
| Q4 2025 | -31% | +121 points |
| Q3 2025 | -325% | +107324 points |
| Q2 2025 | -1441% | +12576 points |
| Q1 2025 | -1635% | +4267 points |
| Q4 2024 | -152% | -112 points |
EDIT's operating margin was −234% last quarter, up 91 points from the same quarter a year ago.
EDIT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$21.2M | +$10.1M |
| Q2 2026 | -$29.7M | +$20.5M |
| Q1 2026 | -$23.2M | +$24.8M |
| Q4 2025 | -$36.4M | +$14.9M |
| Q3 2025 | -$31.3M | +$24.2M |
| Q2 2025 | -$50.2M | +$10.3M |
| Q1 2025 | -$47.9M | +$3.8M |
| Q4 2024 | -$51.3M | -$27.8M |
EDIT has burned cash in almost every quarter: −$110M over the past year, against −$181M the year before.
EDIT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +29% | +34.3M shares |
| 1 year | +71% | +63.5M shares |
| 3 years | +88% | +72M shares |
| 5 years | +125% | +85.4M shares |
| Available history | +207% | +104M shares |
EDIT has 154M diluted shares, up 71% from a year ago.
EDIT Net Leverage
EDIT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
EDIT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.6 | Neutral |
| Stochastic | 20.1 | Neutral |
EDIT's weekly RSI is 42 (neutral) and its Stochastic is 20 (neutral).
EDIT PE vs Healthcare Sector
EDIT has no meaningful PE right now: it lost money over the past year.
EDIT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.53 | 15% below |
| 20 week MA | $2.79 | 23% below |
| 50 week MA | $2.60 | 18% below |
| 100 week MA | $2.37 | 9.7% below |
| 200 week MA | $4.70 | 54% below |
EDIT is in a downtrend: it's below all five of its weekly moving averages, and 54% below its 200-week average.
EDIT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $30.5 | $83.5 | +174% |
| 2021 | $83.5 | $29.9 | -64% |
| 2022 | $29.9 | $8.84 | -70% |
| 2023 | $8.84 | $10.1 | +15% |
| 2024 | $10.1 | $1.21 | -88% |
| 2025 | $1.21 | $2.17 | +79% |
| 2026 YTD | $2.17 | $2.14 | -1.4% |
EDIT's yearly returns have swung widely, from +174% in 2020 to −88% in 2024. It's down 1.4% so far in 2026.